Track RH — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

RH IRTC · Stock Open RH in new tab

112.15 USD
EPS
-0.85
P/B
21.62
ROE
-22.42
Beta
1.27
Target Price
178.38 USD
Loading chart...
Key Metrics
Earnings dateJuly 30, 2026
EPS-0.85
Book Value4.91
Price to Book21.62
Debt/Equity452.39
% Insiders1.158%
Growth
Revenue Growth0.26%
Estimates
Forward P/E99.92
Forward EPS1.06
Target Mean Price178.38

DCF Valuation

Tweak assumptions to recompute fair value for RH (IRTC)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
Current Price
Upside
WACC
Terminal PV
Σ PV of FCFs
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

RH Logo RH Analysis (IRTC)

United States Consumer Discretionary Official Website Stock

Is RH a good investment? RH (IRTC) is currently trading at 112.15 USD. Market analysts have a consensus price target of 178.38 USD. This suggests a potential upside from current levels.

Earnings Schedule: RH is expected to release its next earnings report on July 30, 2026. The market consensus estimate for Forward EPS is 1.06.

Investor FAQ

Does RH pay a dividend?

No, it does not currently pay a dividend.

What asset class is RH?

RH is classified as a Stock.

When is the next earnings date?

The next earnings date is projected to be July 30, 2026. The company currently has a trailing EPS of -0.85.

Company Profile

iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company offers Zio ambulatory cardiac monitoring services, including long-term and short-term continuous monitoring and mobile cardiac telemetry monitoring services. It also provides Zio Monitor System, a prescription-only remote electrocardiogram (ECG) monitoring system consisting a patch ECG monitor that records the electric signal from the heart continuously for up to 14 days; Zio XT System, a prescription-only remote ECG monitoring system that consists of the Zio XT patch that records the electric signal from the heart continuously for up to 14 days; and Zio ECG Utilization Software System, which supports the capture and analysis of ECG data. In addition, the company offers Zio AT System, a prescription-only remote ECG monitoring system, which consists of the Zio AT patch that records the electric signal from the heart continuously for up to 14 days, as well as incorporates the Zio AT wireless gateway to provide connectivity between the patch and the ZEUS System during the patient wear period. It has a development collaboration agreement with BioIS to develop and commercialize pulse oximetry, accelerometry, and trending non-invasive blood pressure technologies for use within ambulatory cardiac monitoring products and services. The company was formerly known as iRhythm Technologies, Inc. and changed its name to iRhythm Holdings, Inc. in January 2026. iRhythm Holdings, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion